Further clinical studies of larger cohorts of mutated T315I CML patients are obviously necessary to clarify the sensitivity of the T315I mutation to HHT in vivo and to guide appropriate therapeutic decisions in these imatinib-resistant CML patients with very poor prognosis. Nevertheless, we are encouraged by the promising results observed with HHT treatment in our patient, which may provide a new alternative therapeutic treatment option for CML patients with the T315I mutation, for whom therapies have been previously lacking. Clinical studies are ongoing. 
JAK2V617F is a recurrent mutation in the classic BCR-ABLnegative myeloproliferative disorders (MPDs); allelic frequency is estimated at 95% for polycythemia vera (PV) and 50% each for essential thrombocythemia (ET) and primary myelofibrosis (PMF). 1 More recently, other JAK2 mutations (exon 12 mutations) have been described in JAK2V617F-negative PV and MPL mutations (MPLW515L/K) in PMF and ET. JAK2V617F occurs in hematopoietic stem cells and myeloid-lineage cells, and some studies have suggested lymphocyte involvement as well: in natural killer, 2 as well as in T and B lymphocytes. 3 However, T-cell involvement was not recognized in many of the initial JAK2V617F studies, 4, 5 including those that used sensitive allele-specific (AS)-PCR assays. 6 Obviously, a negative study in this regard does not exclude the possibility that T-cell involvement is either limited to only a subset of JAK2V617F-positive cases, or is accompanied by an allele burden that is below the limit of detection for a particular mutation screening assay, especially if PCR sequencing is used alone. At the same time, however, the use of ultrasensitive assays could produce false-positive results in the absence of a myeloid cell contamination-free T-cell enrichment process.
To clarify the issue of T-lymphocyte involvement, we prospectively studied four PMF patients harboring MPLW515 mutations (two each with MPLW515L and MPLW515K), and two PV patients harboring homozygous JAK2V617F. The current study was approved by our institutional review board, and all patients provided verbal and written informed consent for study participation. In each case, peripheral blood mononuclear cells (PBMC) were cultured in vitro to yield CD4 þ T lymphocytes. PBMC or granulocytes were isolated by double Ficoll separation as described previously. 5 T-lymphocyte expansion was performed using the Dynabeads s CD3/CD28 T cell expander kit (Dynal, Oslo, Norway), as per protocol. Briefly, previously frozen PBMC were thawed and plated in X-vivo medium (Lonza, Walkersville, MD, USA) with 5% fetal calf serum (FCS) at Figure 1 Purity of in vitro expanded CD4 þ T lymphocytes by flow cytometry analysis. T-lymphocyte population on day 9 is 499.9% pure by CD4 staining.
Letters to the Editor 2 Â 10 6 cells/ml. Dynabeads were added (150 ml) and cells incubated at 371C. On day 3, human recombinant interleukin (rIL)-2 (100 U/ml) was added. On days 5 and 7, the cells were washed in a Big Easy EasySep s magnet (Stem Cell Technologies, Vancouver, CA, USA), and re-suspended in culture medium with IL-2 at 0.5 Â 10 6 cells/ml. Cells were harvested on day 9 for flow cytometric analysis of purity as follows: an aliquot of expanded T lymphocytes was resuspended in 1 Â phosphatebuffered saline þ 3% FCS, and stained with CD4-FITC or isotype control antibodies in the dark at room temperature for 15 min. T-lymphocyte purity was analyzed using a FACS Calibur flow cytometry with CellQuest Pro Software (BD Biosciences, San Jose, CA, USA). We obtained a virtually homogenous population of CD4 þ T lymphocytes (B100% pure) (Figure 1) . T-lymphocyte genotyping for JAK2V617F and MPLW515 mutations was performed by PCR sequencing as described previously.
7 MPLW515K was clearly demonstrated in T lymphocytes in one patient (Figure 2) . However, because PCR sequencing was used to screen for the relevant MPL mutations in T cells, the presence of low levels of mutant allele copies (that is, below the threshold of detection by DNA sequencing;o5-10%) in the remaining cases with MPL mutations cannot be definitively excluded. In contrast, neither of the two cases that harbored homozygous JAK2V617F was found to carry the mutation in the purified T lymphocytes (Figure 2) . Absence of JAK2V617F was confirmed with a highly sensitive AS-PCR assay (sensitivity of mutant allele detection p1%). 8 We can therefore conclude that MPLW515K involves CD4 þ T lymphocytes in some patients with PMF whereas such cells might not be part of the JAK2V617F clone in PV. The current results support our previous observations regarding JAK2V617F distribution in various cell lineages in PV and myelofibrosis 5 and further suggest that MPLW515 mutations, in contrast to JAK2V617F, either provide a greater growth advantage to lymphoid-lineage cells, or alternatively, occur in a more primitive lympho-myeloid progenitor. Direct experimental evidence to distinguish between these possibilities is currently lacking. MPLW515K, but not JAK2V617F, is identified in in vitro expanded CD4 þ T lymphocytes. Forward sequence traces from patients harboring either MPLW515 mutations (cases 1-4) or JAK2V617F (cases 5 and 6), from peripheral blood mononuclear cells (PBMC; left panels), polymorphonuclear cells (PMN)/granulocytes (middle panels) or expanded CD4 þ T lymphocytes (499.9% pure) (right panels). Sequence trace interpretation: wild-type MPL515 is TGG; MPLW515K is AAG; and MPLW515L is TTG. Wild-type JAK2 is TGT and JAK2V617F is TTT.
